Abstract
Background
Panic disorder is associated with high productivity costs. These costs, which should be included in cost-effectiveness analyses (CEA) from a societal perspective, have a considerable impact on cost-effectiveness estimates. However, they are often omitted in published CEAs. It is therefore uncertain whether choosing a societal perspective changes priority setting in future research as compared to a healthcare perspective.
Objectives
To identify research priorities regarding the cost-effectiveness of an early intervention for subthreshold panic disorder using value of information (VOI) analysis and to investigate to what extent priority setting depends on the perspective.
Methods
We calculated the cost-effectiveness of an early intervention for panic disorder from a healthcare perspective and a societal perspective. We performed a VOI analysis, which estimates the expected value of eliminating the uncertainty surrounding cost-effectiveness estimates, for both perspectives.
Results
From a healthcare perspective the early intervention was more effective at higher costs compared to usual care ((sic)17,144 per QALY), whereas it was cost-saving from a societal perspective. Additional research to eliminate parameter uncertainty was valued at (sic)129.7 million from a healthcare perspective and (sic)29.5 million from a societal perspective. Additional research on the early intervention utility gain was most valuable from a healthcare perspective, whereas from a societal perspective additional research would generate little added value.
Conclusions
Priority setting for future research differed substantially according to the perspective. Our study underlines that the health-economic perspective of CEAs on interventions for panic disorder must be chosen carefully in order to avoid inappropriate choices in research priorities.
Original language | English |
---|---|
Article number | 0205876 |
Number of pages | 13 |
Journal | PLOS ONE |
Volume | 13 |
Issue number | 11 |
DOIs | |
Publication status | Published - 7 Nov 2018 |
Keywords
- RANDOMIZED CONTROLLED-TRIAL
- COST-EFFECTIVENESS
- ECONOMIC EVALUATIONS
- UNCERTAINTY
- THERAPY
- PREVENTION
- MODELS